Anzeige
Mehr »
Login
Montag, 21.04.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Gold auf 4.000 USD? Goldman Sachs sagen Ja - und bei Forge sitzt der Ex-CFO von Newmont mit am Tisch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P0G | ISIN: US76090R3093 | Ticker-Symbol: 24O
NASDAQ
21.04.25
21:59 Uhr
0,383 US-Dollar
+0,073
+23,70 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
RESHAPE LIFESCIENCES INC Chart 1 Jahr
5-Tage-Chart
RESHAPE LIFESCIENCES INC 5-Tage-Chart

Aktuelle News zur RESHAPE LIFESCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
RESHAPE LIFESCIENCES Aktie jetzt für 0€ handeln
22:12ReShape Lifesciences Inc. - 8-K, Current Report1
14:54ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology2
14:36ReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology3
10.04.Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket3
09.04.ReShape Lifesciences Inc: ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market514IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed...
► Artikel lesen
07.04.ReShape Lifesciences Inc: ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update77Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad...
► Artikel lesen
06.04.ReShape Lifesciences: Finanzielle Herausforderungen und Marktchancen4
02.04.ReShape Lifesciences Inc. - 8-K, Current Report7
01.04.ReShape Lifesciences Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4053
01.04.ReShape Lifesciences Stock Surges 249%17
20.03.ReShape Lifesciences Inc. - 8-K, Current Report6
10.03.ReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology153IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company...
► Artikel lesen
25.02.ReShape Lifesciences Inc: ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX1
20.02.ReShape Lifesciences Inc. - 8-K, Current Report-
19.02.Pre-market Movers: Sintx Technologies, Cycurion, OSR Holdings, ReShape Lifesciences, NewGenIvf Group583BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Sintx Technologies, Inc. (SINT) is up over 87%...
► Artikel lesen
17.02.ReShape Lifesciences prices $6M public offering3
16.02.ReShape Lifesciences Inc: ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering5
13.02.ReShape Lifesciences Inc. - S-1/A, General form for registration of securities-
06.02.ReShape Lifesciences Inc. - S-1/A, General form for registration of securities1
03.02.ReShape Lifesciences sichert sich wichtiges Patent für Diabetes-Behandlung2
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1